• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Incyte

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
June 13, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
June 13, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
June 08, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
May 30, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
May 12, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
May 01, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
April 29, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
April 28, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
April 28, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 21, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report First Quarter Financial Results
April 09, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 28, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Executive Leadership Appointments
March 25, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 20, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
March 06, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
February 17, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
February 10, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
January 27, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
January 05, 2026
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
December 22, 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
December 22, 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conference
December 18, 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
December 17, 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces Change to its Board of Directors
December 12, 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
December 07, 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
December 07, 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
December 02, 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
December 01, 2025
From Incyte
Via Business Wire
Tickers INCY
News headline image
Incyte to Present at Upcoming Investor Conferences
November 19, 2025
From Incyte
Via Business Wire
Tickers INCY
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap